Nitrogen Bonded To Carbon In Z Moiety Patents (Class 514/538)
-
Publication number: 20140088192Abstract: The invention features methods compositions and infusion pumps for infusing levodopa prodrugs (e.g., levodopa esters, levodopa amides, levodopa carboxamides, and levodopa sulfonamides) for the treatment of Parkinson's disease.Type: ApplicationFiled: December 12, 2011Publication date: March 27, 2014Applicant: SynAgile CorporationInventors: Ephraim Heller, Adam Heller
-
Publication number: 20140066503Abstract: A method of treating tachycardia while minimizing and/or controlling hypotension associated with such treatment includes administering a therapeutically effective amount of a pharmaceutical composition comprising the S-isomer of esmolol to a subject in need thereof.Type: ApplicationFiled: November 8, 2013Publication date: March 6, 2014Applicants: BAXTER INTERNATIONAL INC.Inventors: Barrett Rabinow, Jeff McKee
-
Patent number: 8664257Abstract: The present invention relates to compounds of the formula I, wherein A, D, E, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.Type: GrantFiled: January 26, 2011Date of Patent: March 4, 2014Assignee: SanofiInventors: Sven Ruf, Josef Pernerstorfer, Thorsten Sadowski, Georg Horstick, Herman Schreuder, Christian Buning, Thomas Olpp, Bodo Scheiper, Klaus Wirth
-
Patent number: 8658564Abstract: The present invention relates to novel active compound combinations comprising the known fungicidally active compounds N-[2-(1,3-dimethylbutyl)phenyl]-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide, metalaxyl and triazole (3), which are highly suitable for controlling unwanted phytopathogenic fungi. Moreover, the invention relates to a method for the curative or preventive treatment of phytopathogenic fungi on plants or useful plants, in particular to the treatment of seed, for example seed of cereals, and not least to the treated seed itself.Type: GrantFiled: May 28, 2008Date of Patent: February 25, 2014Assignee: Bayer Cropscience AGInventors: Anne Suty-Heinze, Peter Dahmen
-
Patent number: 8642650Abstract: The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions. In certain embodiments, the invention provides a method of treating an overweight or obese subject including administering a MetAP2 inhibitor in which the amount administered does not substantially modulate angiogenesis.Type: GrantFiled: December 4, 2009Date of Patent: February 4, 2014Assignee: Zafgen, Inc.Inventors: Thomas E. Hughes, James E. Vath
-
Patent number: 8637058Abstract: Composition for controlling phytopathogens comprising compound of the formula: wherein: R1 represents H, or a CO—R? acyl group; R2, the same or different when n is equal to 2, is a halogen, optionally selected from fluorine, chlorine, bromine or iodine; a C1-C9 alkyl group; a C1-C9 haloalkyl group; a C1-C9 alkoxyl group; a C1-C9 haloalkoxyl group; a C1-C9 thioalkyl group; a C1-C9 halothioalkyl group; a C3-C9 cycloalkyl group; a C2-C10 carboalkoxyl group; a cyano group; a hydroxyl group; R? represents a hydrogen; a C1-C9 alkyl group; a C1-C9 haloalkyl group; a C1-C9 alkoxyl group; a C1-C9 haloalkoxyl group; a C2-C10 carboalkoxyl group; a phenyl group; n is a number ranging from 0 to 2; X represents an oxygen atom, a nitrogen or sulfur atom in combination with a fungicide; method for controlling phytopathogens with compound of formula (1) with or without another fungicide.Type: GrantFiled: November 18, 2002Date of Patent: January 28, 2014Assignee: Isagro S.p.A.Inventors: Lucio Filippini, Marilena Gusmeroli, Alexia Elmini, Carlo Garavaglia, Luigi Mirenna
-
Patent number: 8618164Abstract: The field involves compositions useful for pain relief, including diclofenac solution and gel formulations, in particular methods of use thereof, articles of manufacture and kits that provide novel preclinical, clinical and other information to users.Type: GrantFiled: March 4, 2010Date of Patent: December 31, 2013Assignee: Nuvo Research Inc.Inventors: Jagat Singh, Joseph Zev Shainhouse, Bradley S. Galer, Robert Dominic King-Smith, Lisa Marie Grierson, Maria Burian, Jonathan Wilkin, Edward T. Kisak, John M. Newsam
-
Publication number: 20130345678Abstract: A method, medicated feminine sanitary products and compositions for reducing menstrual blood loss in a female are provided. The method comprises delivering an active agent to the uterine cavity by administering intravaginally to the female a therapeutically effective amount of the active agent on a medicated feminine sanitary product during menstrual bleeding, wherein the medicated feminine sanitary product is routinely utilized to absorb the menstrual flow, wherein the active agent is incorporated in the medicated feminine sanitary product as a pharmaceutically acceptable composition, the active agent is any of an antifibrinolytic and a hemostatic agent.Type: ApplicationFiled: August 22, 2013Publication date: December 26, 2013Applicant: ARSTAT Inc.Inventor: Arkady RUBIN
-
Publication number: 20130331423Abstract: The present invention relates to a new formulation of an enkephalinase inhibitor, such as racecadotril or dexecadotril, the process for the preparation thereof, and the use thereof in the treatment of diarrhoea.Type: ApplicationFiled: December 9, 2011Publication date: December 12, 2013Applicant: BIOPROJETInventors: Jean-Stéphane Julien, Marc Maury, Jeanne-Marie Lecomte, Xavier Ligneau, Philippe Robert, Jean-Charles Schwartz
-
Patent number: 8604068Abstract: The present invention comprises 2-cyanobenzenesulfonic acid amides of the formula (I) and isomeric forms thereof (I-A) and (I-B) wherein R1, R2, R3, R4, R5 and A have the aforesaid meaning for the control of animal pests with the use of penetration enhancers and/or ammonium or phosphonium salts.Type: GrantFiled: May 21, 2008Date of Patent: December 10, 2013Assignee: Bayer CropScience AGInventors: Reiner Fischer, Bernd Alig, Christian Arnold, Rolf Pontzen, Klaus-Helmut Müller
-
Publication number: 20130324399Abstract: Compositions and methods for protecting plants from fungal, bacterial, and viral diseases are provided, which compositions comprise at least one compound that produces systemic acquired resistance and at least one antifungal compound. Compositions of the disclosure may be applied directly to seeds, seedlings, shoots, roots, and/or foliage of the plant to be protected, thereby protecting them from the fungal, bacterial, and viral diseases.Type: ApplicationFiled: August 9, 2011Publication date: December 5, 2013Applicant: Bayer Cropscience LPInventors: Jennifer Riggs, Danise Beadle, Katharine Vuocolo
-
Patent number: 8592438Abstract: A plant disease control composition comprising, as an active ingredient, a compound of formula (I) or a salt thereof, and one or more anilinopyrimidine compounds selected from the group consisting of 4,6-dimethyl-N-phenyl-2-pyrimidinamine, 4-methyl-N-phenyl-6-(1-propynyl)-2-pyrimidinamine and 4-cyclopropyl-6-methyl-N-phenyl-2-pyrimidinamine has an excellent plant disease control effect.Type: GrantFiled: March 16, 2009Date of Patent: November 26, 2013Assignee: Sumitomo Chemical Intellectual Property Service, LtdInventors: Masanao Takaishi, Norio Kimura
-
Patent number: 8586093Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.Type: GrantFiled: February 21, 2013Date of Patent: November 19, 2013Assignee: Civitas TherapeuticsInventors: Blair Jackson, David J. Bennett, Raymond T. Bartus, Dwaine F. Emerich
-
Patent number: 8586631Abstract: Novel calcilytic compounds and methods of using them are provided.Type: GrantFiled: February 11, 2013Date of Patent: November 19, 2013Assignee: GlaxoSmithKline, LLCInventors: Robert W. Marquis, Linda N. Casillas, Joshi M. Ramanjulu, James Francis Callahan
-
Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
Publication number: 20130253056Abstract: Disclosed herein are for example, liquid aqueous compositions that include for example an ester or salt of levodopa, or an ester or salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome, dystonia, and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of levodopa and/or carbidopa or ester and/or salt thereof.Type: ApplicationFiled: March 12, 2013Publication date: September 26, 2013Applicant: Neuroderm, Ltd.Inventors: Mara Nemas, Oron Yacoby-Zeevi -
Patent number: 8541342Abstract: The present invention relates to novel active compound combinations comprising the known fungicidally active compounds N-[2-(1,3-dimethylbutyl)phenyl]-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide, metalaxyl and strobilurin (3), which are highly suitable for controlling unwanted phytopathogenic fungi. Moreover, the invention relates to a method for the curative or preventive treatment of phytopathogenic fungi on plants or useful plants, in particular to the treatment of seed, for example seed of cereals, and not least to the treated seed itself.Type: GrantFiled: May 27, 2008Date of Patent: September 24, 2013Assignee: Bayer Cropsciene AGInventors: Anne Suty-Heinze, Peter Dahmen
-
Publication number: 20130236501Abstract: The present invention provides novel pharmaceutical formulations of a substituted phenylacetic acid ester compound, which is useful as a short-acting sedative hypnotic agent for anesthesia and sedation. The pharmaceutical formulations are oil-in-water emulsions suitable for administration by injection. The invention further provides processes for the preparation of the formulation and the use of the formulation in medical treatment of a mammal.Type: ApplicationFiled: May 12, 2011Publication date: September 12, 2013Applicant: ASTRAZENECA ABInventors: Jonathan Booth, Leigh Dixon, Clive Washington
-
Publication number: 20130203601Abstract: Stabilized liquid agrochemical compositions are provided that comprise flowable, aqueous dispersion concentrates comprising a) a continuous aqueous liquid phase; b) at least one dispersed, solid phase comprising a dispersion of polymer particles having a mean particle size of at least one micron, wherein the outside surfaces of the particles comprise a colloidal solid material and wherein the particles have at least one agrochemically active ingredient distributed therein, optionally a non-porous particulate mineral that acts as a diffusion barrier to slow the release of the active ingredient, and optionally at least one non-cross-linkable mobile chemical such that the extraction of this chemical from the disperse phase renders it porous in a manner that allows the active ingredient to diffuse out. The colloidal solid is used to stabilize the polymenzable resin in an emulsion state during preparation.Type: ApplicationFiled: June 7, 2011Publication date: August 8, 2013Applicant: SYNGENTA CROP PROTECTION LLCInventors: Jeffrey David Fowler, Sejong Kim
-
Publication number: 20130190397Abstract: Disclosed is a compound having an acceleration effect on the secretion of human ?-defensin, LL-37, which is a human-derived anti-microbial peptide, a method for preparing same, and a composition for accelerating the secretion of anti-microbial peptide having same as an active ingredient, and the compound and the composition using same of the present invention enhance the anti-microbial effect and the immunity control effect that the anti-microbial peptide has in the body by accelerating the secretion of the anti-microbial peptide in the body.Type: ApplicationFiled: February 27, 2013Publication date: July 25, 2013Applicant: NEOPHARM CO., LTD.Inventor: Neopharm Co., Ltd.
-
Patent number: 8486999Abstract: [PROBLEMS TO BE SOLVED] It is an object of the present invention to provide a gelator containing a long chain oxyaminopolyol capable of forming a gel with a small amount thereof over a liquid property range from acidic to alkaline, and a gel having high environmental suitability, biocompatibility and biodegradability. [MEANS FOR SOLVING THE PROBLEMS] A gelator, characterized by containing a long chain oxyaminopolyol of Formula (I): (where R1 is a C12-16 saturated aliphatic group or a C12-16 unsaturated aliphatic group having one double bond; R2 is a substituent which an amino acid has; and X is an oxygen atom or NH) and a pharmaceutically acceptable salt thereof; a self-assembly formed by the self-assembly of the gelator; and a gel containing the gelator or the self-assembly, and water, an aqueous solution, a hydrophilic organic solvent or a hydrophilic organic solution, or a hydrophobic organic solvent or a hydrophobic organic solution.Type: GrantFiled: January 25, 2010Date of Patent: July 16, 2013Assignee: Nissan Chemical Industries, Ltd.Inventor: Tatsuo Maruyama
-
Publication number: 20130157990Abstract: A method of detoxifying a patient addicted to at least one drug comprises the step of administering a first-medication component to the patient for mitigating drug withdrawal symptoms of the patient. The method further comprises the step of administering an anesthetic component to the patient for putting the patient in a sedated state. The method further comprises the step of administering a detoxification component to the patient for detoxifying the patient of the drug(s) while the patient is in the sedated state. The detoxification component can comprise naloxone. The method further comprises the step of administering a second-medication component to the patient for further mitigating drug withdrawal symptoms of the patient while the patient is in the sedated state. The second-medication component can comprise naltrexone. The method further comprises the step of terminating administration of the anesthetic component to the patient for reviving the patient from the sedated state.Type: ApplicationFiled: February 20, 2013Publication date: June 20, 2013Applicant: EAGLE ADVANCEMENT INSTITUTE LLCInventor: EAGLE ADVANCEMENT INSTITUTE LLC
-
Publication number: 20130150346Abstract: The present disclosure relates to methods of using fatty acid amide hydrolase (FAAH) inhibitors to treat aspects of Parkinson's disease (PD), restless legs syndrome (RLS) and periodic limb movement disorder (PLMD), the use of FAAH inhibitors for the manufacture of medicaments for use in the treatment of PD, RLS and PLMD, as well as pharmaceutically acceptable compositions comprising FAAH inhibitors for use in the treatment of PD, RLS and PLMD.Type: ApplicationFiled: January 7, 2011Publication date: June 13, 2013Applicants: Ironwood Pharmaceutical, Inc.Inventors: James Philip Pearson, Todd G. Milne, Thomas Henry Johnston, Jonathan Michael Brotchie
-
Publication number: 20130123356Abstract: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof,Type: ApplicationFiled: October 18, 2012Publication date: May 16, 2013Applicant: UNIVERSITY COLLEGE LONDONInventors: Masahiro Okuyama, David Selwood, Cristina Visintin, David Baker, Gareth Pryce
-
Publication number: 20130123185Abstract: In certain embodiments, the disclosure relates to methods of treating or preventing organ inflammation or failure such as pulmonary inflammation comprising administering a heme scavenger such as hemopexin to a subject in need thereof. The subject may be diagnosed with higher than normal levels of protein-free plasma heme or a hemolytic disorder such as sickle cell disease, autoimmune hemolytic anemia, or paroxysmal nocturnal hemoglobinuria or acute lung injury or acute chest syndrome. Typically, the hemopexin is recombinant human hemopexin.Type: ApplicationFiled: August 5, 2011Publication date: May 16, 2013Applicant: EMORY UNIVERSITYInventors: Solomon Ofori-Acquah, Samit Ghosh
-
Publication number: 20130109674Abstract: The present invention relates to, among other things, methods for treating trigeminal cephalgias such as migraine and migraine like headaches and other cerebrovascular conditions associated with pain and or inflammation. When non-steroidal anti inflammatory drugs (NSAIDs), such as ketoprofen, are applied locally using specific topical formulations immediate relief of pain is obtained. Intense pain is typically reduced to mild pain or no pain within 30 minutes of application of the topical formulation. The NSAID may be given in combination with other pharmacological agents, such as vasoconstrictors, opioids, decongestants and/or non-opioid migraine drugs, such as triptans and ergots and agents that affect serotonin receptors as agonists, antagonists or partial agonists.Type: ApplicationFiled: December 17, 2010Publication date: May 2, 2013Applicant: Achelios Therapeutics LLCInventors: Harry J. Leighton, Matthew J. Buderer, Crist J. Frangakis
-
Patent number: 8426467Abstract: A concentrated esmolol formulation is provided that is distinguishable from a diluted form of the concentrated esmolol formulation.Type: GrantFiled: May 22, 2007Date of Patent: April 23, 2013Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Deepak Tiwari, George Owoo, Rekha Nayak, Kenneth E. Burhop
-
Patent number: 8404276Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.Type: GrantFiled: December 20, 2010Date of Patent: March 26, 2013Assignee: Civitas Therapeutics, Inc.Inventors: Blair Jackson, David J. Bennett, Raymond T. Bartus, Dwaine F. Emerich
-
Publication number: 20130072551Abstract: The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.Type: ApplicationFiled: November 16, 2012Publication date: March 21, 2013Applicant: UNIVERSITE VICTOR SEGALEN - BORDEAUX 2Inventor: Universite Victor Segalen-Bordeaux 2
-
Publication number: 20130072520Abstract: Compounds of formula (I) have antibacterial activity: wherein R represents hydrogen or 1, 2 or 3 optional substituents; W is ?C(R1)— or ?N—; R1 is hydrogen or an optional substituent and R2 is hydrogen, methyl, or fluorine; or R1 and R2 taken together are —CH2—, —CH2CH2—, —O—, or, in either orientation, —O—CH2— or —OCH2CH2—; R3 is a radical of formula -(Alk1)m-(Z)p-(Alk2)n-Q wherein m, p and n are independently 0 or 1, provided that at least one of m, p and n is 1, Z is —O—, —S—, —S(O)—, —S(O2)—, —NH—, —N(CH3)—, —N(CH2CH3)—, —C(?O)—, —O—(C?O)—, —C(?O)—O—, or an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted divalent bicyclic heterocyclic radical having 5 to 10 ring atoms; Alk1 and Alk2 are optionally substituted C1-C6 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene radicals, which may optionally terminate with or be interrupted by —O—, —S—, —S(O)—, —S(O2)—, —NH—, —N(CH3)—, or —N(CH2CH3)—; and Q is hydrogen, halogen, nitType: ApplicationFiled: November 28, 2011Publication date: March 21, 2013Applicant: Biota Scientific Management Pty LtdInventors: David BROWN, Ian COLLINS, Lloyd CZAPLEWSKI, David HAYDON
-
Publication number: 20130045952Abstract: The present invention relates to ABA agonist compounds which increase plant stress resistance. The invention also relates to methods of using these compounds. The invention further relates to compositions and formulations comprising the ABA agonist compounds, and uses thereof.Type: ApplicationFiled: August 17, 2012Publication date: February 21, 2013Applicant: Van Andel Research InstituteInventors: Yong Xu, Xiaoyin Edward Zhou, Karsten Melcher, Huaqiang Eric Xu
-
Publication number: 20130046004Abstract: The present invention relates to compounds of the formula I, wherein A, D, E, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.Type: ApplicationFiled: January 26, 2011Publication date: February 21, 2013Applicant: SANOFIInventors: Sven Ruf, Josef Pernerstorfer, Thorsten Sadowski, Georg Horstick, Herman Schreuder, Christian Buning, Thomas Olpp, Bodo Scheiper, Klaus Wirth
-
Publication number: 20130046000Abstract: The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent.Type: ApplicationFiled: January 26, 2011Publication date: February 21, 2013Inventor: Naomi Kitamoto
-
Patent number: 8367721Abstract: The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions. In certain embodiments, the invention provides a method of treating an overweight or obese subject including administering a MetAP2 inhibitor in which the amount administered does not substantially modulate angiogenesis.Type: GrantFiled: August 7, 2012Date of Patent: February 5, 2013Assignee: Zafgen, Inc.Inventors: Thomas E. Hughes, James E. Vath
-
Patent number: 8362243Abstract: The present invention relates to novel methods for selective localization of active agents both at and in mitochondria within living cells, as well as corresponding active agents that penetrate through the cell membrane into the cells without further adjuvants and there can be localized both at and in mitochondria. These active agents are substituted with at least one monohydroxy mononitrophenyl rest or monohydroxy dinitrophenyl rest.Type: GrantFiled: October 23, 2007Date of Patent: January 29, 2013Assignee: Ugichem Gesellschaft fuer Organische Chemie mbHInventors: Thomas Lindhorst, Birgit Werner, Stefan Piper
-
Patent number: 8357398Abstract: Oral dosage forms of benzonatate useful for anti-tussive and anti-tussive/combination applications.Type: GrantFiled: October 20, 2010Date of Patent: January 22, 2013Assignee: Alitair Pharmaceuticals Inc.Inventors: William Wayne Howard, Russell Francis Somma, Doreen Marie Frank
-
Publication number: 20120301402Abstract: A method for assessing if a subject has or is at risk of developing cardiac arrhythmia is described. The method includes determining the activity of Rap1A protein in a bodily sample of the subject and comparing the activity of Rap1A protein from the bodily sample of the subject to at least one Rap1A control. A decreased level of Rap1A activity in the bodily sample of the subject as compared to the at least one Rap1A control indicates that the subject is at risk of developing or has cardiac arrhythmia. Methods for evaluating the efficacy of treatment of a subject having decreased Rap1A activity with an antiarrhythmic agent are also described.Type: ApplicationFiled: April 27, 2012Publication date: November 29, 2012Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventors: Maqsood Ahmed Chotani, John Anthony Bauer, Mandar Shankar Joshi, Selvi Chrysolyte Jeyaraj
-
Publication number: 20120302637Abstract: A method of treating tachycardia while minimizing and/or controlling hypotension associated with such treatment includes administering a therapeutically effective amount of a pharmaceutical composition comprising the S-isomer of esmolol to a subject in need thereof.Type: ApplicationFiled: January 26, 2012Publication date: November 29, 2012Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Barrett Rabinow, Jeff McKee
-
Patent number: 8309606Abstract: The present invention provides compounds, pharmaceutical compositions and methods for treating, immuno-allergical diseases, autoimmune diseases, and organ or tissue rejection following transplantation.Type: GrantFiled: August 21, 2009Date of Patent: November 13, 2012Assignee: Novaremed LimitedInventor: Eliahu Kaplan
-
Patent number: 8309766Abstract: The present invention relates to novel phenyl-N-acyl derivatives of biogenic amines and amino acids of general formula (I) as cyclooxynease inhibitors, possessing analgetic and anti-inflammatory properties and devoid of side effects in particular ulcerogeneity and pro-spasmodic actions, as well as capability to potentiate effect of other analgetics, and possessing in addition antihypoxic, antidepressant and anti-Parkinsonistic action; as well as to the processes for the preparation novel and known phenyl-N-acyl derivatives of biogenic amines, to a pharmaceutical composition and to an agent comprising compounds of general formula (I) as well as to use thereof and a method of treating.Type: GrantFiled: March 24, 2006Date of Patent: November 13, 2012Assignee: Obschestvo S. Organichennoi Otvetstvennostiyu PharmenterprisesInventors: Vladimir Evgenievich Nebolsin, Tatyana Alexandrovna Kromova, Galina Alexandrovna Zheltukhina, Violetta Leonidovna Kovaleva
-
Publication number: 20120282180Abstract: The present invention relates to the field of therapeutic and diagnostic agents and more specifically to compounds of formula (I) that are inhibitors of matrix-metalloproteinases (MMPs) and are useful in the treatment of diseases related thereto such as cardiovascular diseases, inflammatory diseases and malignant diseases. One embodiment of the invention is a compound of formula (I) labeled with a 18-fluorine atom having matrix metalloproteinase inhibitory activity suitable for diagnostic imaging. Also disclosed in the present invention is a pharmaceutical composition comprising the inhibitors of matrix-metalloproteinases (MMPs) of the invention or the corresponding labeled compounds useful as diagnostic imaging agents of the invention in a form suitable for mammalian administration.Type: ApplicationFiled: June 8, 2011Publication date: November 8, 2012Inventors: Hartmuth C. Kolb, Guenter Haufe, Malte Behrends, Klaus Kopka, Stefan Wagner, Verena Hugenberg, Hans-Joerg Breyholz, Sven Hermann, Michael Schaefers
-
Publication number: 20120283249Abstract: The subject matter of the present invention is novel families of compounds which are aromatic amine, imine, aminoadamantane and benzodiazepine derivatives, medicaments comprising same and the use thereof as inhibitors of the toxic effects of toxins with intracellular activity, such as, for example, ricin, and of viruses that use the internalization pathway for infecting cells.Type: ApplicationFiled: June 17, 2009Publication date: November 8, 2012Inventors: Roman Lopez, Séverine Hebbe, Daniel Gillet, Julien Barbier
-
Publication number: 20120277309Abstract: A pharmaceutical composition comprising (S)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate in a concentration between about 75 mM and about 150 mM, which is substantially free of the R-isomer or pharmaceutically acceptable salt thereof, is provided. A method of treating a cardiac disorder is also provided and includes administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising (S)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride, wherein the (S)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride is present at a concentration between about 75 mM and about 150 mM and wherein the pharmaceutical composition is substantially free of (R)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate or pharmaceutically acceptable salt thereof.Type: ApplicationFiled: January 26, 2012Publication date: November 1, 2012Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Jerome H. Gass, Jeff McKee, Barrett Rabinow
-
Publication number: 20120270876Abstract: Methods are provided for treating a subject for a condition caused by an abnormality in the subject's autonomic nervous system. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is pharmacologically modulated with at least one beta-blocker in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, where such conditions include various disease conditions. Also provided are systems and kits for use in practicing the subject methods.Type: ApplicationFiled: April 24, 2012Publication date: October 25, 2012Inventors: Anthony Joonkyoo Yun, Patrick Yuarn-Bor Lee
-
Publication number: 20120264703Abstract: The present invention provides novel methods and formulations for treating anxiety disorders, including Post Traumatic Stress Disorder, in human subjects employing coordinate treatment using ? and ? blockers alone or in combination with additional psychotherapeutic medications to treat the anxiety disorder and reduce symptomology in treated subjects.Type: ApplicationFiled: June 15, 2012Publication date: October 18, 2012Inventors: Arifulla Khan, John Frederick Reinhard, JR.
-
Publication number: 20120196930Abstract: This invention relates to a new topical gel formulation of the drug Esmolol hydrochloride for treatment of chronic wounds such as diabetic wounds, burn wounds, venous ulcers and pressure ulcers.Type: ApplicationFiled: September 21, 2010Publication date: August 2, 2012Applicant: VLIFE SCIENCES TECHNOLOGIES PVT. LTD.Inventors: Supreet K. Deshpande, Sudhir A. Kulkarni, Reena Gollapudy
-
Publication number: 20120190649Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.Type: ApplicationFiled: August 5, 2010Publication date: July 26, 2012Applicant: BIOGEN IDEC MA INC.Inventors: Jermaine Thomas, Xiaogao Liu, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Arthur G. Taveras
-
Patent number: 8222294Abstract: The present invention concerns combinations of an anti-emetic agent and an enkephalinase inhibitor for use in methods for treating diarrhea and/or gastroenteritis.Type: GrantFiled: February 14, 2005Date of Patent: July 17, 2012Assignee: BioprojectInventors: Jean-Charles Schwartz, Jeanne-Marie Lecomte
-
Patent number: 8216971Abstract: The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against phyto-pathogenic fungi or damaging insects, and the corresponding methods of treatment using the said composition. More precisely, the subject of the present invention is a pesticide composition based on propamocarb-HCl, an insecticide active substance and optionally a further fungicide active substance.Type: GrantFiled: December 21, 2007Date of Patent: July 10, 2012Assignee: Bayer Intellectual Property GmbHInventors: Koen van Den Eynde, Wolfgang Thielert, Heike Hungenberg
-
Publication number: 20120172392Abstract: Compositions and methods are disclosed for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1). The compounds disclosed are amine-containing and amide-containing compounds. The compounds and compositions are useful for treatment of diseases, including inflammation, inflammatory diseases and autoimmune disorders.Type: ApplicationFiled: March 7, 2012Publication date: July 5, 2012Inventors: LUISA M. SALTER-CID, ERIC Y. WANG, MARY T. MACDONALD, JINGJING ZHAO
-
Patent number: RE43711Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.Type: GrantFiled: October 17, 2011Date of Patent: October 2, 2012Assignee: Civitas Therapeutics, Inc.Inventors: Blair Jackson, David J. Bennett, Raymond T. Bartus, Dwaine F. Emerich